期刊
BIOMED RESEARCH INTERNATIONAL
卷 2016, 期 -, 页码 -出版社
HINDAWI LTD
DOI: 10.1155/2016/2076061
关键词
-
资金
- NPU of MEYS [LO1309]
- [IGA MZ NT 13477-4]
- [PRVOUK 37/06]
The purpose of this prospective controlled study was to compare healing quality following the implantation of ultraporous beta-tricalcium phosphate, containing either expanded autologous mesenchymal stromal cells (trial group, 9 patients) or beta-tricalcium phosphate alone (control group, 9 patients), into femoral defects during revision total hip arthroplasty. Both groups were assessed using the Harris Hip Score, radiography, and DEXA scanning at 6 weeks and 3, 6, and 12 months postoperatively. A significant difference in the bone defect healing was observed between both groups of patients (P < 0.05). In the trial group, trabecular remodeling was found in all nine patients and in the control group, in 1 patient only. Whereas, over the 12-month follow-up period, no significant difference was observed between both groups of patients in terms of the resorption of beta-tricalcium phosphate, the significant differences were documented in the presence of radiolucency and bone trabeculation through the defect (P < 0.05). Using autologous mesenchymal stromal cells combined with a beta-tricalcium phosphate scaffold is a feasible, safe, and effective approach for management of bone defects with compromised microenvironment. The clinical trial was registered at the EU Clinical Trials Register before patient recruitment has begun (EudraCT number 2012-005599-33).
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据